Creation of a Biocollection of Patients With Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) or High-risk Myelodysplastic Syndrome (MDS) Monitored at the Nantes University Hospital

NCT06681363 | Not Yet Recruiting

• 2 other identifiers: RC24_04832024-A1986-41
• Study Type: observational
• Target: 1,000
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of the LANA bio-collection is to collect samples from patients with Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL) or or high-risk myelodysplastic syndrome (MDS) to facilitate access to the leukemic or myelodysplastic cells for the research teams of the National Institute of Health and Medical Research (INSERM). To do this, an additional blood or bone marrow sample to those planned in the context of patient care will be collected after signing consent. These samples will then be sent directly to the INSERM teams for immediate analysis with the aim to conduct research aimed at a better understanding of AML, ALL or MDS and improving treatments

Conditions

Acute Myeloid Leucemia; High-risk Myelodysplastic Syndrome (MDS); Acute Lymphoid Leukemia

Keywords

high-risk myelodysplactic syndrome; Acute leukemia

Outcome Measures

Primary Outcomes (1)

• Characterization of the tumor and its microenvironment for AML, ALL or MDS in order to identify novel biomarkers or therapeutic targets

  Identify genetic polymorphisms associated with an increased risk of developing AML or ALL

  One year after inclusion

Study Arms (1)

Patients with high-risk AML, ALL or MDS

Patients with high-risk AML, ALL or MDS treated in the hematology department of Nantes University Hospital. According to the needs of ongoing biological studies, additional volumes may be collected during blood and bone marrow sampling for diagnosis or relapse at inclusion , with up to one additional sample each month for three months following inclusion

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with high-risk AML, ALL, or MDS managed in the hematology department of the University Hospital of Nantes

You may qualify if:

• Patient of legal age affected by AML, ALL or MDS regardless of the time of treatment
• Patient who has signed the consent form.
• Patient affiliated with a social security system.

You may not qualify if:

• Minor patients.
• Adults under guardianship.
• Protected persons

Sponsors & Collaborators

• Nantes University Hospital: lead

Study Sites (1)

Nantes University Hospital

Nantes, France

Location

Biospecimen

Retention: SAMPLES WITH DNA

Blood and bone narrow samples

MeSH Terms

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Condition Hierarchy (Ancestors)

Leukemia, Lymphoid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Study Officials

• Pierre Peterlin

  Nantes University Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Pierre Perterlin

CONTACT

+33 2 40 08 32 71; Pierre.PETERLIN@chu-nantes.fr

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 5, 2024
• First Posted: November 8, 2024
• Study Start (Estimated): June 15, 2026
• Primary Completion (Estimated): June 15, 2036
• Study Completion (Estimated): June 15, 2036
• Last Updated: April 15, 2026

Record last verified: 2026-04

Locations

FR (1)